Consolidated Statement of Operations - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Total revenue	$ 18,845,000	$ 22,270,000
Operating expenses:
Research and development	92,965,000	50,519,000
General and administrative	26,722,000	20,077,000
Loss on impairment of in-process research and development	0	22,123,000
Total operating expenses	119,687,000	92,719,000
Loss from operations	100,842,000	70,449,000
Interest and other income, net	1,028,000	2,323,000
Interest and other expense, net	(1,705,000)	(1,298,000)
Loss on extinguishment of debt	(1,237,000)	0
Loss on disposal of assets	(2,155,000)	0
Change in fair value of warrant liabilities	0	3,000
Loss before provision for income taxes	104,911,000	69,421,000
Provision for income taxes	5,000.00	0.00
Net loss	104,916,000	69,421,000
Net loss attributable to common shareholders	$ 104,916,000	$ 69,421,000
Net loss per share attributable to common shareholders:
Basic and diluted	$ 2.20	$ 1.86
Weighted average number of shares used in net loss per share calculations:
Basic and diluted	47,603,261	37,770,378
Research And Development Revenue | Other
Total revenue	$ 9,068,000	$ 0
Research And Development Revenue | Related Party
Total revenue	6,567,000	19,499,000
Grant
Total revenue	$ 3,210,000	$ 2,771,000